



## Fresenius Medical Care

### Conflict Minerals Policy Statement

As the leading manufacturer and provider of dialysis equipment and services, with shares listed on the New York Stock Exchange, Fresenius Medical Care AG & Co. KGaA, together with its subsidiaries ("Fresenius Medical Care"), is subject to the provisions of Section 1502 of the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) relating to "**Conflict Minerals.**" Section 1502 of the Dodd-Frank Act and SEC Rule 13p-1 addresses the sourcing of 3TG minerals (Tin, Tantalum, Tungsten, and Gold) from the Democratic Republic of the Congo ("DRC") and adjoining countries ("Covered Countries") which are known locations where armed groups mine and sell these minerals to finance civil violence.

The sourcing activities of Fresenius relating to conflict minerals are in compliance with US federal law, specifically the Dodd-Frank Wall Street Reform and Consumer Protection Act, Section 1502. Fresenius Medical Care has implemented due diligence procedures in accordance with the Organization for Economic Co-operation and Development ("OECD") Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-affected and High-Risk Areas with the intent of providing supply chain transparency.

Fresenius Medical Care is committed to compliance with Section 1502 of the Dodd-Frank Act and encourages our suppliers to foster similar commitments of their supply chain related to conflict minerals disclosures.